Accelerate Diagnostics Inc (NASDAQ:AXDX) was the recipient of unusually large options trading on Monday. Stock traders acquired 3,074 call options on the company. This is an increase of approximately 713% compared to the typical volume of 378 call options.

Accelerate Diagnostics (NASDAQ:AXDX) traded up $0.35 during midday trading on Wednesday, hitting $23.25. The stock had a trading volume of 415,977 shares, compared to its average volume of 283,132. The company has a market capitalization of $1,290.00, a price-to-earnings ratio of -19.38 and a beta of 2.19. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45.

In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 5,500 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $22.00 per share, with a total value of $121,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 50.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. lifted its position in shares of Accelerate Diagnostics by 7.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,236 shares of the medical research company’s stock worth $3,207,000 after buying an additional 7,930 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Accelerate Diagnostics by 21.2% in the second quarter. Wells Fargo & Company MN now owns 73,328 shares of the medical research company’s stock worth $2,005,000 after buying an additional 12,840 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Accelerate Diagnostics by 7.4% in the second quarter. Alliancebernstein L.P. now owns 35,010 shares of the medical research company’s stock worth $958,000 after buying an additional 2,400 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Accelerate Diagnostics by 20.7% in the second quarter. Teachers Advisors LLC now owns 47,200 shares of the medical research company’s stock worth $1,291,000 after buying an additional 8,095 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its position in shares of Accelerate Diagnostics by 12.6% in the second quarter. TIAA CREF Investment Management LLC now owns 69,821 shares of the medical research company’s stock worth $1,910,000 after buying an additional 7,796 shares in the last quarter. 47.56% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently weighed in on AXDX. ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. BidaskClub lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Finally, BTIG Research lowered Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $33.00.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/14/investors-purchase-large-volume-of-call-options-on-accelerate-diagnostics-axdx.html.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.